BIMINI Biotech has secured an investment of €200,000 to further develop its technology

Utrecht Holdings proudly announces that UMC Utrecht and University Utrecht jointly entered into a License- and Collaboration agreement with BIMINI Biotech B.V.

BIMINI Biotech B.V. is a spinoff from UMC Utrecht devoted to further develop novel therapies for cancer patients, further building on the knowledge of Prof dr Ger Strous on the targeting of the Growh Hormone Receptor. Hereto BIMINI Biotech obtained a first investment from the Proof-of-Concept fund UNIIQ.

press relaese:

UNIIQ invests €200,000 in novel cancer therapeutics startup BIMINI Biotech